SNORA86: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORA86

NCBI ID: G106633814

SNORA86

Other Name(s): small nucleolar RNA, H/ACA box 86 | Small nucleolar RNA, H/ACA box 86

SNORA86: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Small nucleolar RNA (snRNA), also known as microRNA (miRNA), is a non-coding RNA molecule that plays a crucial role in regulating gene expression in various organisms, including humans. One of the well-known snRNAs is H/ACA box 86 (SNORA86), which has been shown to have various functions in various cellular processes. Although the primary function of SNORA86 is not well understood, research has identified its potential as a drug target or biomarker. In this article, we will explore the potential of SNORA86 as a drug target and its potential as a biomarker for various diseases.

The H/ACA box 86 (SNORA86) is a 24nt RNA molecule that is located within the 86th exon of the X chromosome. It is a part of the non-coding RNA molecule class and has been shown to play a role in various cellular processes, including DNA replication, gene expression, and cell signaling.

Recent studies have identified SNORA86 as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and metabolic diseases. One of the reasons for its potential as a drug target is its unique structure, which allows it to interact with various signaling molecules. SNORA86 has been shown to interact with various nuclear proteins, including histone proteins, non-histone proteins, and RNA molecules. Additionally, its expression has been shown to be regulated by various signaling pathways, including TGF-灏?, NF-kappa-B, and PI3K/AKT signaling pathways.

Another reason for its potential as a drug target is its involvement in various diseases, including cancer. Several studies have shown that SNORA86 is overexpressed or downregulated in various types of cancer, including breast cancer, lung cancer, and colorectal cancer. Additionally, its expression has been shown to be associated with various negative outcomes in cancer, including poor prognosis and increased risk of recurrence. Therefore, targeting SNORA86 may be an effective way to treat various types of cancer.

In addition to its potential as a drug target, SNORA86 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be regulated by various signaling pathways, including TGF-灏?, NF-kappa-B, and PI3K/AKT signaling pathways. Additionally, its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and metabolic diseases. Therefore, measuring the expression of SNORA86 may be an effective way to diagnose and monitor various diseases.

In conclusion, SNORA86 is a small nucleolar RNA that has various functions in cellular processes. Its unique structure and its involvement in various diseases make it an attractive target for drug development. Further research is needed to fully understand the potential of SNORA86 as a drug target and its potential as a biomarker for various diseases.

Protein Name: Small Nucleolar RNA, H/ACA Box 86

The "SNORA86 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA86 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets